For example, for subependymal giant cell astrocytoma (SEGA) associated with the tumor predisposition syndrome tuberous sclerosis, the mTOR inhibitor everolimus is now FDA-approved in the upfront setting based on a landmark phase 3 clinical trial showing its efficacy (15). This evidence concerns the gene MTOR and subependymal giant cell astrocytoma.